Sticking with that trade front, President Trump says he's spoken to Indian Prime Minister Narendra Modi, in a move that could ease tensions between the two major economies. The call came after the two nations resumed trade negotiations. Let's get more with our senior editor, Derek Wallbank, joining us for more.I mean, Derek, I found it so interesting. You can see in that social media post that he said he had a wonderful call with India's Narendra Modi. But how did that become a wonderful call.When you look ...

We are sort of fortunate right now that a lot of our product is is made in Mexico which is exempt under the uh trade agreement right now but we don't let our guard down. We don't assume you know anything. Um we still think we've got pricing power.We don't want to go there but because we as I said we want to continue to deliver just a great value proposition to the consumers. I think it's pretty tough to all of a sudden uh have much of your production made in America. I think the cost I think getting labor t ...

Core Insights - The pharmaceutical industry has historically been protected from tariffs due to long-standing trade agreements, but the current administration's focus on bringing manufacturing back to the U.S. poses new challenges [1][2] - President Trump has proposed tariffs of up to 25% on imported pharmaceuticals, with potential updates expected in early April [2] - The imposition of tariffs would represent a significant shift for the industry, reversing the effects of a 1994 World Trade Organization agreement that eliminated levies on many pharmaceutical products [3] Industry Impact - Analysts indicate that the pharmaceutical companies have benefited from low tax rates in countries like Ireland, which has attracted U.S. pharmaceutical firms [4] - The complexities of global tax strategies and supply chains may delay companies' ability to adjust to new tariffs, leading to potential negative impacts [5] - Companies such as Merck, AbbVie, Amgen, and Pfizer are identified as facing the highest risks from potential tariffs, while others like Eli Lilly and Gilead have more moderate risks [6]